| __timestamp | Axsome Therapeutics, Inc. | HUTCHMED (China) Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 4279200 | 33472000 |
| Thursday, January 1, 2015 | 6776987 | 47368000 |
| Friday, January 1, 2016 | 21199860 | 66871000 |
| Sunday, January 1, 2017 | 19957616 | 50675000 |
| Monday, January 1, 2018 | 23495055 | 78821000 |
| Tuesday, January 1, 2019 | 53647067 | 91944000 |
| Wednesday, January 1, 2020 | 70244579 | 111234000 |
| Friday, January 1, 2021 | 58060725 | 207447000 |
| Saturday, January 1, 2022 | 57947447 | 267587000 |
| Sunday, January 1, 2023 | 97944000 | 303055000 |
| Monday, January 1, 2024 | 187077000 |
Infusing magic into the data realm
In the dynamic world of pharmaceuticals, research and development (R&D) is the lifeblood of innovation. Axsome Therapeutics, Inc. and HUTCHMED (China) Limited exemplify this commitment, with their R&D expenditures revealing intriguing trends over the past decade. From 2014 to 2023, Axsome's R&D spending surged by over 2,000%, peaking in 2023. Meanwhile, HUTCHMED consistently outpaced Axsome, with its R&D expenses growing nearly tenfold, reaching a zenith in 2023. This strategic allocation underscores their dedication to pioneering treatments and therapies. Notably, HUTCHMED's R&D investment in 2023 was approximately three times that of Axsome, highlighting its aggressive pursuit of innovation. These trends not only reflect the companies' growth trajectories but also their unwavering commitment to advancing healthcare solutions. As the pharmaceutical landscape evolves, such investments will likely continue to shape the future of medicine.
Analyzing R&D Budgets: Amgen Inc. vs HUTCHMED (China) Limited
Research and Development: Comparing Key Metrics for Bristol-Myers Squibb Company and Axsome Therapeutics, Inc.
Takeda Pharmaceutical Company Limited or HUTCHMED (China) Limited: Who Invests More in Innovation?
Biogen Inc. or HUTCHMED (China) Limited: Who Invests More in Innovation?
R&D Spending Showdown: BioMarin Pharmaceutical Inc. vs HUTCHMED (China) Limited
Comparing Innovation Spending: Madrigal Pharmaceuticals, Inc. and HUTCHMED (China) Limited
Research and Development Investment: Grifols, S.A. vs HUTCHMED (China) Limited
Opthea Limited vs HUTCHMED (China) Limited: Strategic Focus on R&D Spending
Research and Development Investment: Axsome Therapeutics, Inc. vs Alpine Immune Sciences, Inc.
Research and Development Expenses Breakdown: Viking Therapeutics, Inc. vs HUTCHMED (China) Limited
Research and Development Expenses Breakdown: Vericel Corporation vs HUTCHMED (China) Limited
Analyzing R&D Budgets: HUTCHMED (China) Limited vs Geron Corporation